Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
|Articles|April 1, 2012
- Applied Clinical Trials-04-01-2012
- Volume 21
- Issue 4
Applied Clinical Trials Digital Edition - April 2012
INFORMATION TECHNOLOGY : Enhancing Risk Assessment and Mitigation REGULATORY : Sunshine Act?s Impact on the Industry Implementation of Objective Internal Monitoring Also in this issue : Impact of Transparency Policies, EMA?s Executive Director Faces Multiple Challenges, The Roles of Healthcare and Research, HIV Vaccine Trials
Advertisement
Articles in this issue
over 14 years ago
Business and News Update April 2012over 14 years ago
Transparency, Sunshine Shape Researchover 14 years ago
When Worlds Collide: Healthcare and Researchover 14 years ago
CRO Founded to Address Neglected Diseases in Under Served Countriesover 14 years ago
EFGCP Acts to Reduce Ethics Problemsover 14 years ago
Sunshine Act's Impactover 14 years ago
Keeping a Cool Head Amidst Turmoilover 14 years ago
Startup Offers New Take on Recruitmentover 14 years ago
Risk Assessment and MitigationAdvertisement
Related to this article
Paradigm’s Kurt Mussina touches on why he rejects the “site management organization” model in favor of one unified business.
ProofPilot’s Lauren Briggs talks on why sponsors and CROs fail at tech rollouts by skipping change management, and pushes for the industry to judge trial technology by real workflow impact rather than feature checklists.
ProofPilot’s Lauren Briggs touches on why site tech adoption hinges on the first 90 days after rollout, and why tools succeed only when they remove work from a site’s plate rather than adding another login to juggle.
Jennifer Byrne, CEO, Javara touches on why fixing clinical research requires sustained infrastructure investment and workforce development.
Sequoia’s Dan White and Dr. Tom Kreamer touch on why sponsors and CROs should treat a site network as one centralized partnerto speed startup timelines and strengthen execution.
Sequoia Clinical Research’s CEO Dan White and CMO, Dr. Tom Kreamer explain what it takes to merge three site organizations into one network.
Javara CEO Jennifer Byrne talks about the requirements for embedding clinical trials directly into physician practices and why solving the “last mile” of trial participation means building infrastructure at the actual point of care.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
2026 SCRS Global Site Solutions Summit: What Should Sponsors and CROs Change About How They Contract with a Network?
2
What It Actually Means to Embed AI Across the Clinical Operating Model
3
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
4
2026 SCRS Global Site Solutions Summit: What's a Mistake Sponsors or CROs Make When Rolling Out New Trial Technology?
5